NEW YORK, Sept. 28, 2016 /PRNewswire/ -- A panel of federal judges will soon consider a proposal to centralize all federally-filed Taxotere lawsuits (http://www.rxinjuryhelp.com/taxotere/lawsuit/) alleging permanent hair loss in a single federal court for the purposes of coordinated pretrial proceedings. According to court documents, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear oral arguments on the matter during its next Hearing Session, which is scheduled to be convened on Thursday, September 28th, in Washington, D.C. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm has heard from numerous women who allegedly experienced permanent alopecia following breast cancer chemotherapy with Taxotere. This indicates that the litigation involving the drug could be large, and may well warrant the type of centralization being considered by the Panel," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others whose hair failed to grow back following chemotherapy with Taxotere.
Taxotere and Permanent Hair Loss
Sanofi-Aventis obtained U.S. regulatory approval for Taxotere in 1996 to treat breast cancer. The chemotherapy agent's approved uses have since been expanded to cover a number of cancers, including head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. While the drug has been on the market for two decades, it wasn't until December 2015 that any information regarding reports of permanent hair loss was included on its U.S. label.
Court records indicate that more than 50 Taxotere lawsuits have been filed in federal courts on behalf of patients who allegedly experienced permanent alopecia following treatment with the medication. While hair loss is a common side effect of chemotherapy, plaintiffs claim that Taxotere is more likely to result in permanent alopecia compared to alternative, equally effective agents. While Sanofi-Aventis did provide information regarding the potential for permanent hair loss to individual patients and regulatory agencies overseas, Taxotere plaintiffs claim that the U.S. label only included a generic, vague, and insufficient warning that "hair generally grows back"
In July, two Taxotere plaintiffs filed a motion with the JPML seeking centralization of all federally-filed hair loss lawsuits in the U.S. District Court, Eastern District of Louisiana. While Sanofi-Aventis agrees that centralization of the federal Taxotere docket is appropriate, it has proposed that the cases be transferred to the U.S. District Court, District of New Jersey.
Cancer patients who allegedly experienced permanent alopecia following Taxotere chemotherapy may be entitled to compensation for their emotional distress and other damages. To learn more about Taxotere lawsuits, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP